Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride

Agnihotri, 2009, Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine: NBM, 5, 90, 10.1016/j.nano.2008.07.003 Atkins, 1990 Basak, 2008, Design and release characteristics of sustained release tablet containing metformin HCl, Braz. J. Pharm. Sci., 44, 477 Blasi, 2005, Plasticizing effect of water on poly(lactide-co-glycolide), J. Control. Release, 108, 1, 10.1016/j.jconrel.2005.07.009 Brodbeck, 1999, Phase inversion dynamics of PLGA solutions related to drug delivery: Part II. The role of solution thermodynamics and bath-side mass transfer, J. Control. Release, 62, 333, 10.1016/S0168-3659(99)00159-5 Dunn, R.L., English, P., Vanderbilt, P., 1990. Biodegradable in-situ forming implants and methods of producing the same [14,938,763]. Patent 4938763 Fox, 2009, Squalene emulsions for parenteral vaccine and drug delivery, Molecules, 14, 3286, 10.3390/molecules14093286 Graves, 2007, In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: a technical note, AAPS Pharm. Sci. Technol., 8, 10.1208/pt0803062 Himanshu, 2010, Parfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery, Nanomedicine: Nanotechnol. Biol. Med., 6, 324, 10.1016/j.nano.2009.10.004 Hutchings, 2007, Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat, Neurotoxicol. Teratol., 17, 419, 10.1016/0892-0362(94)00079-S Johnson, 2005, Buprenorphine: considerations for pain management, J. Pain Symptom Manage., 29, 297, 10.1016/j.jpainsymman.2004.07.005 Kempe, 2008, Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process, J. Control. Release, 130, 220, 10.1016/j.jconrel.2008.06.006 Liu, 2010, Electrospun PLGA/collagen nanofibrous membrane as early-stage wound dressing, J. Membr. Sci., 355, 53, 10.1016/j.memsci.2010.03.012 Loeb, 1963, Sea water demineralization by means of an osmotic membrane, Adv. Chem. Ser., 38, 117, 10.1021/ba-1963-0038.ch009 Luan, 2006, Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems, J. Control. Release, 110, 266, 10.1016/j.jconrel.2005.10.005 Mohamadnia, 2009, Investigation of drug release and 1H-NMR analysis of the in situ forming systems based on poly(lactide-co-glycolide, Polym. Adv. Technol., 20, 48, 10.1002/pat.1279 Ofokansi, 2009, The use of liquid self-microemulsifying drug delivery systems based on peanut oil/Tween 80 in the delivery of griseofulvin, Drug Dev. Ind. Pharm., 35, 185, 10.1080/03639040802244292 Packhaeuser, 2004, In situ forming parenteral drug delivery systems: an overview, Eur. J. Pharm. Biopharm., 58, 445, 10.1016/j.ejpb.2004.03.003 Patel, 2007, Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate, AAPS J., 9, 344, 10.1208/aapsj0903041 Pignatello, 2002, Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen, Eur. J. Pharm. Sci., 16, 53, 10.1016/S0928-0987(02)00057-X Rafienia, 2009, Influence of poly (lactide-co-glycolide) type and gamma irradiation on the betamethasone acetate release from the in situ forming systems, Curr. Drug Deliv., 6, 184, 10.2174/156720109787846243 Ravivarapu, 2000, Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate, J. Pharm. Sci., 89, 732, 10.1002/(SICI)1520-6017(200006)89:6<732::AID-JPS4>3.0.CO;2-D Sakr, 2011, Effect of Kollidon SR on the release of Albuterol Sulphate from matrix tablets, Saudi Pharm. J., 19, 19, 10.1016/j.jsps.2010.11.002 Schuh, 1999, Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet, Drug Alcohol Depend., 56, 55, 10.1016/S0376-8716(99)00012-5 Shoaib, 2006, Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC, Pak. J. Pharm. Sci., 19, 119 Singhal, 2007, Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance, Addict. Behav., 32, 320, 10.1016/j.addbeh.2006.05.003 Stamatialis, 2008, Medical applications of membranes: drug delivery, artificial organs and tissue engineering, J. Membr. Sci., 308, 1, 10.1016/j.memsci.2007.09.059 Wang, 2009, Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection, Eur. J. Pharm. Sci., 38, 138, 10.1016/j.ejps.2009.06.008 Wang, 2009, Design and optimization of a new self-nanoemulsifying drug delivery system, J. Colloid Interface Sci., 330, 443, 10.1016/j.jcis.2008.10.077 Wilding, 1996, Pharmacokinetic evaluation of transdermal buprenorphine in man, Int. J. Pharm., 132, 81, 10.1016/0378-5173(96)85198-2 Young, 2001, Investigation of the drug distribution and release characteristics from particulate membranes, J. Membr. Sci., 191, 199, 10.1016/S0376-7388(01)00471-9